CONTACT AN EXPERT
Bring the power of precision medicine to more veterans.
With nearly 50,000 incident cancer cases are reported by Veterans Affairs (VA) annually, there is an urgent need to develop diagnostic and therapeutic strategies that deliver actionable insights to serve better a patient population who first served us.
Biomarker-based companion diagnostics (CDx) help identify alterations in a patient’s cancer and molecularly matches them to the appropriate FDA-cleared or approved targeted therapies, immunotherapies and clinical trials for the following cancer indications:
Informing urothelial cancer therapy decisions
QIAGEN’s therascreen FGFR RGQ RT-PCR Kit is a FDA-approved companion diagnostic test to help identify patients with urothelial cancer who are eligible for treatment with BALVERSA™ (erdafitinib).
Guiding treatment decisions for patients with breast cancer
QIAGEN’s therascreen PIK3CA RGQ PCR Kit is the first FDA-approved companion diagnostic test to help identify patients with advanced breast cancer who are eligible for treatment with the ∝-selective PI3K-inhibitor PIQRAY (alpelisib).
Diagnosing myeloproliferative neoplasms (MPNs)
QIAGEN’s ipsogen JAK2 RGQ PCR Kit is a FDA-cleared IVD for the detection of the JAK2 V617F/G1849T allele, a major criterion for the diagnosis of all MPNs in the WHO (World Health Organization) guidelines.
Testing for KRAS mutations in colorectal cancer
QIAGEN’s therascreen KRAS RGQ PCR Kit is a FDA-approved companion diagnostic to help identify patients with colorectal cancer who are eligible for treatment with ERBITUX (cetuximab) and Vectibix.
read more
Customizing PCR and NGS applications with an end-to-end workflow
Whatever your area of medical research, QIAGEN’s complete NGS solution generates actionable insights with an integrated bioinformatics pipeline.